Concord Biotech Ltd successfully completes Russian GMP insepction at its API facility

Concord Biotech Limited has announced the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22' 2025 to July 25' 2025.

This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance across all aspects of our operations. It reflects our dedication to excellence and our continued focus on meeting the rigorous requirements of global regulatory authorities.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1879.20 as compared to the previous close of Rs. 1928.55. The total number of shares traded during the day was 7553 in over 1134 trades.

The stock hit an intraday high of Rs. 1950.00 and intraday low of 1863.40. The net turnover during the day was Rs. 14431956.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 SuccessfulCompletion RussianGMPInspection APIFacility Dholka